Frank P. Kroon

5.8k citations

87 papers · 3.8k indexed · 1 hit paper · h-index 31

Epidemiology top 1%
Infectious Diseases top 0.5%
Immunology top 2%
Virology top 0.5%
Hepatology top 2%

Co-authors: Jaap T. van Dissel J.C. de Jong L. B. S. Gelinck R. van Furth Mark de Boer Tom H. M. Ottenhoff Tjitske de Boer Jean‐Laurent Casanova
Topics: HIV/AIDS drug development and treatment (28 papers)HIV Research and Treatment (27 papers)HIV/AIDS Research and Interventions (24 papers)
Cited by: Virology Infectious Diseases Epidemiology
Journals: Science The Journal of Experimental Medicine PLoS ONE
Partner nations: Netherlands United States United Kingdom

In The Last Decade

Frank P. Kroon

87 papers receiving 3.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Severe Mycobacterial and Salmonella Infections in Interleukin-12 Receptor-Deficient Patients

1998 640 citations Tjitske de Boer, Jaap T. van Dissel et al. profile →

Peers

Countries citing papers authored by Frank P. Kroon

Since Specialization

Citations

This map shows the geographic impact of Frank P. Kroon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frank P. Kroon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frank P. Kroon more than expected).

Fields of papers citing papers by Frank P. Kroon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frank P. Kroon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frank P. Kroon. The network helps show where Frank P. Kroon may publish in the future.

Co-authorship network of co-authors of Frank P. Kroon

This figure shows the co-authorship network connecting the top 25 collaborators of Frank P. Kroon. A scholar is included among the top collaborators of Frank P. Kroon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frank P. Kroon. Frank P. Kroon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Randomised, placebo-controlled trial to evaluate clinical efficacy and structure modifying properties of subcutaneous etanercept in patients with erosive inflammatory hand osteoarthritis 2017 ·Osteoarthritis and Cartilage ·M. Kloppenburg,Roberta Ramonda,Wing‐Yee Kwok,Klaus Bobacz,Dirk Elewaut,Paola Frallonardo,T. Huizinga,Frank P. Kroon,Josef S Smolen,Bert Vander Cruyssen,Ron Wolterbeek,Leonardo Punzi,Gust Verbruggen,Ruth Wittoek	3
2	A Survey of Patients’ Perspectives on Outpatient HIV Care in the Netherlands 2017 ·Infectious Diseases and Therapy ·(unknown),Colette Smit,Frank P. Kroon,Pythia T. Nieuwkerk,Peter Reiss,Kees Brinkman,Suzanne E. Geerlings	6
3	Impact of HIV care facility characteristics on the cascade of care in HIV-infected patients in the Netherlands 2015 ·AIDS ·(unknown),Colette Smit,Ard van Sighem,Peter Reiss,Pythia T. Nieuwkerk,Frank P. Kroon,Kees Brinkman,Suzanne E. Geerlings	10
4	Durability of protective antibody titres is not enhanced by a two-dose schedule of an ASO3-adjuvanted pandemic H1N1 influenza vaccine in adult HIV-1-infected patients 2014 ·Scandinavian Journal of Infectious Diseases ·Markus Bickel,(unknown),Imke Wieters,Frank P. Kroon,Hans Wilhelm Doerr,Eva Herrmann,(unknown),Oliver Jung,Regina Allwinn,Christoph Stephan	2
5	Risk factors for Pneumocystis jirovecii pneumonia in kidney transplant recipients and appraisal of strategies for selective use of chemoprophylaxis 2011 ·Transplant Infectious Disease ·Mark de Boer,Frank P. Kroon,Saskia le Cessie,Johan W. de Fijter,Jaap T. van Dissel	59
6	Potential Influence of More-Sensitive HIV-1 Load Detection by the new Roche Cobas AmpliPrep/Cobas TaqMan Version 2.0 Assay on Clinical Management of HIV-Positive Pregnant Women 2010 ·Journal of Clinical Microbiology ·Mark de Boer,Els Wessels,Eric C. J. Claas,Frank P. Kroon	7
7	Transient Lowering of the Viral Set Point After Temporary Antiretroviral Therapy of Primary HIV Type 1 Infection 2010 ·AIDS Research and Human Retroviruses ·Radjin Steingrover,(unknown),Irene G. M. van Valkengoed,Vincent Bekker,Daniela Bezemer,Frank P. Kroon,(unknown),Maria Prins,Frank de Wolf,Joep M. A. Lange,Jan M. Prins	20
8	Immunological Analysis of Treatment Interruption After Early Highly Active Antiretroviral Therapy 2010 ·Viral Immunology ·Ingrid M. M. Schellens,Katalin Pogány,Geertje H. A. Westerlaken,José A. M. Borghans,Frank Miedema,Irene G. M. van Valkengoed,Frank P. Kroon,Joep M. A. Lange,Kees Brinkman,Jan M. Prins,Debbie van Baarle	1
9	Severe course of Lyme neuroborreliosis in an HIV-1 positive patient; case report and review of the literature 2010 ·BMC Neurology ·Nathalie D. van Burgel,Mayke Oosterloo,Frank P. Kroon,Alje P. van Dam	8
10	Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals 2003 ·AIDS ·David M. Burger,Patricia W. H. Hugen,Peter Reiss,Inge C. Gyssens,M. M. E. Schneider,Frank P. Kroon,Gerrit Schreij,Kees Brinkman,Clemens Richter,Jan M. Prins,Rob E. Aarnoutse,Joep M. A. Lange	119
11	No drug–drug interaction between nelfinavir or indinavir and mefloquine in HIV-1-infected patients 2000 ·AIDS ·Emile F. Schippers,Patricia W. H. Hugen,Ruud J. R. Den Hartigh,David M. Burger,Richard M. W. Hoetelmans,Leo G. Visser,Frank P. Kroon	13
12	Residual Type 1 Immunity in Patients Genetically Deficient for Interleukin 12 Receptor β1 (IL-12Rβ1) 2000 ·The Journal of Experimental Medicine ·Claudia E. Verhagen,Tjitske de Boer,Hermelijn H. Smits,Frank A. W. Verreck,Eddy A. Wierenga,M Kurimoto,David A. Lammas,(unknown),Özden Sanal,Frank P. Kroon,Jaap T. van Dissel,Francesco Sinigaglia,Tom H. M. Ottenhoff	67
13	Enhanced antibody response to pneumococcal polysaccharide vaccine after prior immunization with conjugate pneumococcal vaccine in HIV-infected adults 2000 ·Vaccine ·Frank P. Kroon,Jaap T. van Dissel,(unknown),Peter H. Nibbering,(unknown)	67
14	Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy 1999 ·AIDS ·Nadine G. Pakker,(unknown),Marijke Roos,Sigrid A. Otto,David B. Hall,Ferdinand W.N.M. Wit,Dörte Hamann,(unknown),Frans A.P. Claessen,Robert H. Kauffmann,Peter P. Koopmans,Frank P. Kroon,Chris H.H. ten Napel,Herman G. Sprenger,Hugo M. Weigel,Julio Montaner,Joep M. A. Lange,Peter Reiss,P T Schellekens,Frank Miedema	87
15	Absence of Epstein-Barr virus (EBV) in a gastrointestinal stromal cell tumour (GIST) in an adult human immunodeficiency virus-seropositive patient with past EBV infection 1997 ·European Journal of Gastroenterology & Hepatology ·(unknown),Frank P. Kroon,Pancras C.W. Hogendoorn,(unknown),Roeland A. Veenendaal,Albert de Roos,C. B. H. W. Lamers	13
16	Antibody Response toHaemophilus influenzaeType b Vaccine in Relation to the Number of CD4+ T Lymphocytes in Adults Infected with Human Immunodeficiency Virus 1997 ·Clinical Infectious Diseases ·Frank P. Kroon,Jaap T. van Dissel,Ger T. Rijkers,Jerry Labadie,R. van Furth	22
17	Rejection Treatment and Cytomegalovirus Infection as Risk Factors for Pneumocystis carinii Pneumonia in Renal Transplant Recipients 1996 ·Clinical Infectious Diseases ·Sandra M. Arend,Rudi G. J. Westendorp,Frank P. Kroon,J. W. van’t Wout,Jan P. Vandenbroucke,Leendert A. van Es,Fokko J. van der Woude	83
18	Substitution of Didanosine Sachets by Chewable Tablets 1995 ·Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology ·David M. Burger,Pieter L. Meenhorst,Jan W. Mulder,(unknown),(unknown),Frank P. Kroon,(unknown),(unknown),A. Bult,Jos H. Beijnen	6
19	Antibody Response to Diphtheria, Tetanus, and Poliomyelitis Vaccines in Relation to the Number of CD4+ T Lymphocytes in Adults Infected with Human Immunodeficiency Virus 1995 ·Clinical Infectious Diseases ·Frank P. Kroon,Jaap T. van Dissel,Jerry Labadie,Anton M. van Loon,R. van Furth	80
20	Antibody response to influenza, tetanus and pneumococcal vaccines in HIV-seropositive individuals in relation to the number of CD4+ lymphocytes 1994 ·AIDS ·Frank P. Kroon,Jaap T. van Dissel,J.C. de Jong,(unknown)	186

About Frank P. Kroon

Frank P. Kroon is a scholar working on Virology, Infectious Diseases and Epidemiology, having authored 87 papers that have together received 3.8k indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (28 papers), HIV Research and Treatment (27 papers) and HIV/AIDS Research and Interventions (24 papers). The work is most often cited by research in Virology (846 citations), Infectious Diseases (1.9k citations) and Epidemiology (1.9k citations). Frank P. Kroon has collaborated with scholars based in Netherlands, United States and United Kingdom. Frequent co-authors include Jaap T. van Dissel, J.C. de Jong, L. B. S. Gelinck, R. van Furth, Mark de Boer, Tom H. M. Ottenhoff, Tjitske de Boer, Jean‐Laurent Casanova, Peter Kabel and Frédéric Altare. Their work appears in journals such as Science, The Journal of Experimental Medicine and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact